DALLAS – HME providers in the United States will now have another solution to meet their respiratory patients’ at-home oxygen therapy needs, specifically CAIRE’s new IntenOxy 5 stationary oxygen concentrator. From its global manufacturing headquarters north of Atlanta, the new addition will make its way to Medtrade when the show convenes Feb. 18-20 in Dallas.

According to an article published in the National Library of Medicine database, CMS estimates that more than one million Medicare recipients receive long-term oxygen therapy (LTOT) at home. The IntenOxy 5 offers effective oxygen delivery with up to 95.5 percent concentration and flow settings from 0.5 to 5 liters per minute (LPM), meeting a broad range of prescription needs.

Patients will appreciate its simple user interface with easy-to-understand alerts. Weighing 34.2 lbs., this concentrator is sleek and compact, blending into the surroundings and boasting a low power consumption of <350W at the 5 LPM setting.

When combined with CAIRE’s award-winning FreeStyle Comfort portable oxygen concentrator, the IntenOxy 5 provides yet another solution to help DME and HME customers stock their fleets with what the industry calls non-delivery solutions—equipment that requires minimal maintenance and reduces overall operating expenses. The unit has a three-year warranty and will soon be available in Canada.

“The IntenOxy 5 Stationary Oxygen Concentrator has been an excellent addition to our oxygen therapy portfolio,” said Ken Hosako, CAIRE president and CEO. “The unit is a key component to how our DME and HME customers serve their respiratory patients, providing them with an at-home device that delivers the oxygen they need as they navigate activities of daily living.”

Register Now for Medtrade 2025.